Truist Securities Maintains Buy on CVS Health, Lowers Price Target to $98
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst David Macdonald has maintained a 'Buy' rating on CVS Health (NYSE:CVS), but lowered the price target from $103 to $98.

August 04, 2023 | 1:41 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
CVS Health's price target has been lowered from $103 to $98 by Truist Securities, though the 'Buy' rating is maintained.
The lowering of the price target by Truist Securities could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential upside, which could counterbalance the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100